Quantcast

Industry news that matters to you.  Learn more

BrainScope Announces Publication Describing Proprietary Concussion Biomarker to Assess Potential Severity and Predict Prolonged Recovery

BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, recently announced that researchers have published preliminary results related to a multi-modal concussion assessment capability for potential severity and likelihood of prolonged recovery from concussions.  Published in the peer-reviewed journal Computers in Biology and Medicine, the paper entitled, “A multimodal biomarker for concussion identification, prognosis and management” describes a study which enrolled 568 concussed and matched control patients between the ages of 13-25 from 29 colleges and 19 high schools. Subjects were tested at the time of injury and at multiple time points during recovery.

Launch of Consumer Health Intelligence Service Onegevity Combines Blood, Genome and Microbiome Analysis for Personalized Health and Wellness

January 15 marks the official launch of Onegevity Health as a new consumer health intelligence company, which combines a multi-omic artificial intelligence (AI) platform with consumer-friendly products and digital services. Onegevity will provide a comprehensive molecular portrait and customized recommendations for an individual’s health based on integrated analysis of longitudinal blood, genetics, and gut microbiome profiles.

Roche Receives FDA Approval for VENTANA ALK (D5F3) CDx Assay to Identify Lung Cancer Patients Eligible for Treatment with Roche’s ALECENSA (alectinib)

Roche recently announced it has obtained US Food and Drug Administration (FDA) approval for the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Roche medicine ALECENSA® (alectinib). The VENTANA ALK (D5F3) CDx Assay is the only test FDA-approved as a companion diagnostic for ALECENSA.

Biognosys Announces a Technological Breakthrough in the Development of Its Next-Generation Proteomics Workflow

Biognosys AG announced today a breakthrough in the development of its next generation proteomics technology that helps scientists to understand complex biological processes. For the first time, Biognosys’ data-independent acquisition (DIA) mass spectrometry workflow has identified and quantified more peptides than sequentially possible with data dependent acquisition (DDA) on a Thermo Scientific™ Q Exactive™ HF. The DIA method now provides a clear path to the ultimate life science community goal – to quantify every protein, the complete proteome, in a biological sample of interest. The results of the study have recently been published in the journal Molecular and Cellular Proteomics.

An Updated Biomarker Commons Website

Today, we’ve launched an updated BiomarkerCommons.org website. We’ve kept the clean page style and introduce larger, easier-to-read fonts and a new layout optimized for all your mobile devices.